Invention Grant
- Patent Title: Recombinant laminin-521
- Patent Title (中): 重组层粘连蛋白-521
-
Application No.: US13328145Application Date: 2011-12-16
-
Publication No.: US08415156B2Publication Date: 2013-04-09
- Inventor: Karl Tryggvason , Sergey Rodin
- Applicant: Karl Tryggvason , Sergey Rodin
- Applicant Address: SE Stockholm
- Assignee: Biolamina AB
- Current Assignee: Biolamina AB
- Current Assignee Address: SE Stockholm
- Agency: Fay Sharpe LLP
- Agent Richard M. Klein
- Main IPC: C12N5/00
- IPC: C12N5/00 ; A01N63/00

Abstract:
The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
Public/Granted literature
- US20120156254A1 RECOMBINANT LAMININ-521 Public/Granted day:2012-06-21
Information query